Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study

被引：9
|
作者：
Moreau, Philippe [1 ]
Ghori, Razi [2 ]
Farooqui, Mohammed [2 ]
Marinello, Patricia [2 ]
San Miguel, Jesus [3 ]
机构：
[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France
[2] Merck & Co Inc, Dept Med Oncol, Kenilworth, NJ USA
[3] Clin Univ Navarra, CIMA, IDISNA, CIBERONC,Dept Clin & Translat Med, Pamplona, Spain
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 194卷 / 01期
关键词：
multiple myeloma; immunotherapy; oncology; IMMUNOTHERAPY;
D O I：
10.1111/bjh.17448
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E48 / E51
页数：4
相关论文
共 50 条
  • [1] Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study
    Mateos, Maria-Victoria
    Orlowski, Robert Z.
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    Reece, Donna
    Moreau, Philippe
    Munshi, Nikhil
    Avigan, David E.
    Siegel, David S.
    Ghori, Razi
    Farooqui, Mohammed Z. H.
    Marinello, Patricia
    San-Miguel, Jesus
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (05) : E117 - E121
  • [2] A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
    Derman, Benjamin A.
    Chari, Ajai
    Zonder, Jeffrey
    Major, Ajay
    Stefka, Andrew T.
    Jiang, Ken
    Karrison, Theodore
    Jasielec, Jagoda
    Jakubowiak, Andrzej
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (05) : 564 - 570
  • [3] Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma
    Tiplady, CW
    Summerfield, GP
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) : 381 - 381
  • [4] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [5] A Phase 1 and 2 Study of Filanesib Alone and in Combination With Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Shah, Jatin J.
    Kaufman, Jonathan L.
    Zonder, Jeffrey A.
    Cohen, Adam D.
    Bensinger, William I.
    Hilder, Brandi W.
    Rush, Selena A.
    Walker, Duncan H.
    Tunquist, Brian J.
    Litwiler, Kevin S.
    Ptaszynski, Mieke
    Orlowski, Robert Z.
    Lonial, Sagar
    CANCER, 2017, 123 (23) : 4617 - 4630
  • [6] Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma-A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone
    Slordahl, Tobias S.
    Askeland, Frida Bugge
    Hanssen, Margrete Sofie Saetre
    Hov, Hakon
    Sundt-Hansen, Stine Marie
    Lindahl, Sofia
    Vethe, Nils Tore
    Hjorth-Hansen, Henrik
    Fenstad, Mona H.
    Waage, Anders
    Hjertner, Oyvind
    Schjesvold, Fredrik
    Sundan, Anders
    EJHAEM, 2025, 6 (01):
  • [7] Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study
    Martin Kropff
    Martin Vogel
    Guido Bisping
    Rudolf Schlag
    Rudolf Weide
    Wolfgang Knauf
    Heinrich Fiechtner
    Georgi Kojouharoff
    Stephan Kremers
    Wolfgang E. Berdel
    Annals of Hematology, 2017, 96 : 1857 - 1866
  • [8] Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study
    Kropff, Martin
    Vogel, Martin
    Bisping, Guido
    Schlag, Rudolf
    Weide, Rudolf
    Knauf, Wolfgang
    Fiechtner, Heinrich
    Kojouharoff, Georgi
    Kremers, Stephan
    Berdel, Wolfgang E.
    ANNALS OF HEMATOLOGY, 2017, 96 (11) : 1857 - 1866
  • [9] Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
    Chari, Ajai
    Cornell, Robert F.
    Gasparetto, Cristina
    Karanes, Chatchada
    Matous, Jeffrey V.
    Niesvizky, Ruben
    Lunning, Matthew
    Usmani, Saad Z.
    Anderson, Larry D., Jr.
    Chhabra, Saurabh
    Girnius, Saulius
    Shustik, Chaim
    Stuart, Robert
    Lee, Yihua
    Salman, Zeena
    Liu, Emily
    Valent, Jason
    HEMATOLOGICAL ONCOLOGY, 2020, 38 (03) : 353 - 362
  • [10] Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma
    Sugiura, Isamu
    Terabe, Satomi
    Kinoshita, Tomohiro
    Yamamoto, Kazuhito
    Sawa, Masashi
    Ozawa, Yukiyasu
    Atsuta, Yoshiko
    Suzuki, Ritsuro
    Shimizu, Kazuyuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (04) : 434 - 440
12345